Brezivaptan: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 2: | Line 2: | ||
{{Drugbox | {{Drugbox | ||
| verifiedfields = changed | | verifiedfields = changed | ||
| verifiedrevid = | | verifiedrevid = 477318123 | ||
| image = Brezivaptan.png | | image = Brezivaptan.png | ||
| image_size = 200px | | image_size = 200px | ||
| Line 9: | Line 9: | ||
}} | }} | ||
'''Brezivaptan''' is a pharmaceutical compound that acts as a selective antagonist of the [[vasopressin receptor]] | '''Brezivaptan''' is a pharmaceutical compound that acts as a selective antagonist of the [[vasopressin receptor]]. It is primarily investigated for its potential therapeutic effects in conditions related to the [[endocrine system]], particularly those involving the regulation of water balance and [[blood pressure]]. | ||
==Pharmacology== | ==Pharmacology== | ||
Brezivaptan functions by inhibiting the action of [[vasopressin]], a hormone that plays a crucial role in | Brezivaptan functions by inhibiting the action of [[vasopressin]], a hormone that plays a crucial role in the body's retention of water and the constriction of blood vessels. By blocking the [[vasopressin receptor]], Brezivaptan can potentially reduce water retention and lower blood pressure, making it a candidate for treating conditions such as [[hyponatremia]] and [[congestive heart failure]]. | ||
==Mechanism of Action== | ===Mechanism of Action=== | ||
The mechanism of action of Brezivaptan involves selective antagonism of the V1A receptor, | The primary mechanism of action of Brezivaptan involves its selective antagonism of the [[V1A receptor]], a subtype of the vasopressin receptor. This receptor is predominantly found in vascular smooth muscle and the central nervous system. By blocking this receptor, Brezivaptan reduces vasoconstriction and promotes diuresis, which can be beneficial in managing fluid overload conditions. | ||
==Clinical Applications== | ==Clinical Applications== | ||
Brezivaptan is | Brezivaptan is under investigation for its potential use in treating various medical conditions. Its ability to modulate the effects of vasopressin makes it a promising candidate for managing disorders such as: | ||
* '''Hyponatremia''': A condition characterized by low sodium levels in the blood, often associated with heart failure, liver cirrhosis, and certain kidney diseases. | |||
* '''Heart Failure''': By reducing fluid overload and decreasing vascular resistance, Brezivaptan may help alleviate symptoms of heart failure. | |||
==Development and Research== | ==Development and Research== | ||
Research | Research into Brezivaptan is ongoing, with studies focusing on its efficacy, safety, and potential side effects. Clinical trials are essential to determine the optimal dosing and to identify any long-term impacts of the drug. | ||
==Related pages== | ==Related pages== | ||
* [[Vasopressin receptor antagonist]] | * [[Vasopressin receptor antagonist]] | ||
* [[ | * [[Hyponatremia]] | ||
* [[ | * [[Heart failure]] | ||
[[Category:Vasopressin receptor antagonists]] | [[Category:Vasopressin receptor antagonists]] | ||
[[Category:Experimental drugs]] | [[Category:Experimental drugs]] | ||
Latest revision as of 06:14, 5 March 2025
A vasopressin receptor antagonist
| Brezivaptan | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Brezivaptan is a pharmaceutical compound that acts as a selective antagonist of the vasopressin receptor. It is primarily investigated for its potential therapeutic effects in conditions related to the endocrine system, particularly those involving the regulation of water balance and blood pressure.
Pharmacology[edit]
Brezivaptan functions by inhibiting the action of vasopressin, a hormone that plays a crucial role in the body's retention of water and the constriction of blood vessels. By blocking the vasopressin receptor, Brezivaptan can potentially reduce water retention and lower blood pressure, making it a candidate for treating conditions such as hyponatremia and congestive heart failure.
Mechanism of Action[edit]
The primary mechanism of action of Brezivaptan involves its selective antagonism of the V1A receptor, a subtype of the vasopressin receptor. This receptor is predominantly found in vascular smooth muscle and the central nervous system. By blocking this receptor, Brezivaptan reduces vasoconstriction and promotes diuresis, which can be beneficial in managing fluid overload conditions.
Clinical Applications[edit]
Brezivaptan is under investigation for its potential use in treating various medical conditions. Its ability to modulate the effects of vasopressin makes it a promising candidate for managing disorders such as:
- Hyponatremia: A condition characterized by low sodium levels in the blood, often associated with heart failure, liver cirrhosis, and certain kidney diseases.
- Heart Failure: By reducing fluid overload and decreasing vascular resistance, Brezivaptan may help alleviate symptoms of heart failure.
Development and Research[edit]
Research into Brezivaptan is ongoing, with studies focusing on its efficacy, safety, and potential side effects. Clinical trials are essential to determine the optimal dosing and to identify any long-term impacts of the drug.
